| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income | 188,487 | 124,250 |
| Depreciation and amortization | 48,511 | 32,277 |
| Stock option expense | 24,374 | 18,307 |
| Benefit for deferred income taxes | -16,259 | -13,243 |
| Noncash long-term incentive compensation | 3,057 | 3,273 |
| Litigation settlements | 1,850 | - |
| Noncash directors' compensation | 1,123 | 1,123 |
| Amortization of debt issuance costs | 241 | 160 |
| Increase in accounts receivable | 44,403 | 13,466 |
| (increase)/decrease in inventories | 45 | 955 |
| Increase in prepaid expenses | 8,603 | 7,232 |
| Increase/(decrease) in accounts payable and other current liabilities | 10,102 | -12,449 |
| Change in current income taxes | -2,162 | -10,764 |
| Net change in lease assets and liabilities | 576 | 72 |
| Decrease/(increase) in other assets | -42,048 | -48,426 |
| Increase in other liabilities | 6,355 | 1,521 |
| Other sources | 639 | 194 |
| Net cash provided by operating activities | 254,739 | 171,350 |
| Capital expenditures | 46,447 | 29,088 |
| Proceeds from sale of fixed assets | 3,751 | 480 |
| Business combinations, net of cash acquired | 225 | 225 |
| Other uses | 468 | 322 |
| Net cash used by investing activities | -43,389 | -29,155 |
| Purchases of treasury stock | 256,944 | 76,168 |
| Proceeds from exercise of stock options | 27,152 | 27,152 |
| Dividends paid | 23,196 | 14,542 |
| Capital stock surrendered to pay taxes on stock-based compensation | 8,484 | 8,484 |
| Change in cash overdrafts payable | 610 | 309 |
| Other sources/(uses) | 914 | 1,092 |
| Net cash used by financing activities | -259,948 | -70,641 |
| Decrease in cash and cash equivalents | -48,598 | 71,554 |
| Cash and cash equivalents at beginning of period | 178,350 | - |
| Cash and cash equivalents at end of period | 129,752 | - |
CHEMED CORP (CHE)
CHEMED CORP (CHE)